This has been well documented in the study conducted by the Shukla et al. [49], which demonstrated that apigenin treatment of LNCaP and PC-3 (prostate cancer cell lines) aggravated the levels of ERK1/2 and decreased the phosphorylation levels of p38 kinase. The gene discussed is MAPK3; the disease is Familial prostate cancer.